Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) generates a steady flow of news as a fully integrated, commercial-stage biotechnology company with both marketed products and a broad development pipeline. News coverage for Tonix often centers on its FDA-approved fibromyalgia treatment TONMYA, its acute migraine products Zembrace SymTouch and Tosymra, and updates on clinical and regulatory milestones across central nervous system, immunology, rare disease and infectious disease programs.
Investors following TNXP news can expect announcements on commercial launches, market access decisions, and distribution arrangements for TONMYA, as well as prescription trends and formulary placements for its migraine therapies. The company also regularly reports progress on TNX-102 SL in indications such as acute stress-related conditions and major depressive disorder, including IND clearances and the design of potentially pivotal Phase 2 studies.
Tonix’s immunology and infectious disease work contributes additional news items, including collaborations with academic centers like Massachusetts General Hospital for TNX-1500 in kidney transplantation, and development plans for TNX-4800, a monoclonal antibody designed for seasonal prevention of Lyme disease. Licensing transactions, such as the acquisition of TNX-4900 for chronic neuropathic pain from Rutgers University, and government-supported projects like the DTRA-backed antiviral TNX-4200, are also common themes in company press releases.
This TNXP news page aggregates company-issued updates and related coverage so readers can quickly review developments in Tonix’s commercial operations, clinical pipeline, financing activities, and strategic collaborations. For investors and observers tracking biotech catalysts, revisiting this page provides a concise way to monitor how Tonix’s programs and capital markets actions evolve over time.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced exclusive worldwide licensing of TNX-4900, a selective small-molecule Sigma-1 receptor antagonist for chronic neuropathic pain, on December 16, 2025. TNX-4900 binds human S1R with Ki = 7.5 nM, shows >100-fold selectivity over Sigma-2, and demonstrates high blood-brain barrier penetration and oral bioavailability of ~28%. In animal models of diabetic and chemotherapy-induced neuropathic pain, TNX-4900 produced significant, durable analgesia after acute and chronic dosing without tolerance or motor impairment. Tonix plans expanded PK, formulation, and safety studies to support IND-enabling development.
Tonix Pharmaceuticals (Nasdaq: TNXP) appointed Irina Ishak as General Counsel, effective Dec 8, 2025. Ishak brings more than 25 years of corporate legal and life sciences experience and will lead legal, governance, and compliance functions. She previously served as Senior Counsel at Lowenstein Sandler since 2013 and advised Tonix since 2017 on financings, licensing, commercial agreements, and board matters.
The appointment coincides with Tonix commercializing FDA-approved TONMYA (first new fibromyalgia drug in >15 years) and advancing a diversified CNS, immunology, rare disease, and infectious disease pipeline.
Tonix Pharmaceuticals (NASDAQ: TNXP) announced FDA clearance of an IND to support clinical development of TNX-102 SL 5.6 mg for adults with major depressive disorder (MDD). The IND enables a potentially pivotal Phase 2 HORIZON study: a 6-week, randomized, double-blind, placebo-controlled trial enrolling ~360 patients at ~30 US sites, with primary endpoint of MADRS total score change at Week 6. Tonix plans to begin enrollment in mid-2026. Prior TNX-102 SL studies in fibromyalgia and PTSD showed signals of depressive-symptom improvement on BDI-II and MADRS. The program targets disturbed sleep associated with depression and the company reports prior tolerability data from fibromyalgia registrational studies.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that TONMYA™ (cyclobenzaprine HCl sublingual tablets) is now commercially available by prescription in U.S. pharmacies as of Nov 17, 2025. TONMYA is presented as a first‑in‑class, non‑opioid, once‑daily bedtime analgesic for adults with fibromyalgia and is the first FDA‑approved fibromyalgia treatment in more than 15 years.
The FDA approved TONMYA on Aug 15, 2025 based on two double‑blind Phase 3 trials (nearly 1,000 patients) showing a significant reduction in daily pain at 14 weeks and a higher percentage achieving ≥30% pain improvement; three Phase 3 trials (> 1,400 patients) reported overall tolerability and listed common adverse events.
Tonix Pharmaceuticals (Nasdaq: TNXP) reported third-quarter 2025 results and operational highlights on Nov 10, 2025. Key commercial news: Tonmya (cyclobenzaprine HCl sublingual) received FDA approval as the first new fibromyalgia medicine in >15 years and is set to launch in November 2025 with a WAC established and field sales in place.
Financials: $190.1M cash as of Sept 30, 2025 and a cash runway expected to fund operations into Q1 2027. Q3 product revenue was $3.3M versus $2.8M a year earlier. Q3 net loss was $32.0M (loss per share $3.59) with 8.92M weighted average shares outstanding.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman, M.D., will present at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 10:00 AM ET. A live webcast will be available on the company's Investors Events page, with a replay accessible for 90 days after the event. Investors seeking meetings should contact their Stifel representative.
Business highlights: Tonix is a commercial biotechnology company with FDA approval for TONMYA for fibromyalgia, marketed acute migraine treatments, a CNS and immunology pipeline (including TNX-102 SL, TNX-1500, TNX-2900, TNX-801, TNX-4800) and a DTRA contract for TNX-4200 of up to $34 million over five years.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a collaboration with Massachusetts General Hospital to initiate an investigator‑initiated, open‑label Phase 2 study of Fc‑modified anti‑CD40L mAb TNX‑1500 to prevent kidney transplant rejection.
The study, planned for initiation in first half of 2026 pending IRB approval and FDA IND clearance, will enroll five adult kidney transplant recipients at MGH. TNX‑1500 dosing is monthly for 12 months with induction including anti‑thymocyte globulin, tacrolimus and corticosteroids; tacrolimus is tapered with intent to discontinue by 12 months. The primary endpoint is adverse and serious adverse events at 12 months; secondary endpoints include graft survival, renal function, biopsy‑proven acute rejection and donor‑specific antibodies.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman, M.D. will present at BIO-Europe 2025 on November 4, 2025 at 3:00 p.m. CET in Presenting Company Theater 1 at the Vienna Congress and Convention Center.
The presentation will overview Tonix’s strategy and pipeline, highlighting near-term clinical, regulatory, and commercial milestones. The company markets approved products including Tonmya for fibromyalgia and two acute migraine treatments, and it disclosed a DTRA contract for up to $34 million for TNX-4200. Management meetings can be requested via the BIO One-on-One Partnering system.
Tonix Pharmaceuticals (Nasdaq: TNXP) presented Phase 3 RESILIENT data showing statistically significant pain reduction (p<0.0001) with Tonmya (cyclobenzaprine HCl sublingual tablets) versus placebo in adults with fibromyalgia.
The 14-week, randomized, double-blind trial enrolled 456 intent-to-treat participants across 34 U.S. sites. Tonmya also produced meaningful improvements in sleep, fatigue, and fibromyalgia symptoms/function, and exploratory analyses showed sexual function gains in female participants.
Tonmya was FDA approved on August 15, 2025. Safety findings included low adverse event–related discontinuations (6.1% on Tonmya vs 3.5% placebo) and mostly mild oral mucosal reactions; labeled risks include embryofetal toxicity and serotonin syndrome drug interactions.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced the first patient has been dosed in the investigator‑initiated FOCUS study at Massachusetts General Hospital on Oct 22, 2025. The randomized, double‑blind, placebo‑controlled crossover pilot will evaluate Tonix's intranasal potentiated oxytocin products TNX-2900 (6 IU) and TNX-1900 (24 IU) in adults with arginine‑vasopressin deficiency (AVP‑D), a rare endocrine disorder formerly called central diabetes insipidus.
The study will measure single‑dose effects on anxiety, depression, and socioemotional functioning and include an exploratory two‑week replacement analysis to generate preliminary data to inform future clinical studies.